TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil Versus Propofol for TCI Sedation of Patients Undergoing Gastrointestinal Endoscopic Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing elective higher, lower or mixed gastrointestinal endoscopy at Hospital de San Jose, Bogota, between January and December 2010.~* Be between 18 and 70 years old.~* American Society of Anesthesiology Physical Status classification between 1 and 3.~* Provide written informed consent.~Exclusion Criteria:~* Patients with difficult airway indicators.~* Pregnant women.~* Patients with chronic pain.~* Chronic opioid or benzodiazepine users (\>3 months).~* Allergy history to remifentanil or propofol or eggs.~* Psychoactive drug users.~* Smokers (\> 5 cigarettes per day in the previous 3 months).~* Body mass index \> 30.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Remifentanil (Type: ACTIVE_COMPARATOR): Remifentanil target controlled infusion effect site with Minto's pharmacokinetic model.~Start dose: 1 ng/mL. Titration: 0.5 ng/mL according to clinical criteria.
- Propofol (Type: ACTIVE_COMPARATOR): Propofol target controlled infusion effect site with Marsh's pharmacokinetic model.~Start dose: 1 mcg/mL. Titration: 0.5 mcg/mL according to clinical criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Abuse Liability of Pregabalin and Its Effects on Benzodiazepine Withdrawal Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted to the Medical Withdrawal Unit at the Centre for Addiction and Mental Health for medically assisted withdrawal from benzodiazepines, zopiclone and/or zolpidem~* Willing and capable to give written informed consent~Exclusion Criteria:~* Patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.~* Pregnant or nursing women~* Renal impairment (creatinine clearance less than 60ml/min)~* History of angioedema, or taking drugs associated with angioedema (e.g., ACE-inhibitors).~* Currently taking pregabalin or gabapentin~* Currently taking thiazolidinedione antidiabetic agents (e.g., rosiglitazone, pioglitazone)~* Previous history of pregabalin or gabapentin abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): Pregabalin titrated up to, and tapered from, 225mg/day in divided doses for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
None

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Fatigue in Emergency Center Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients must be admitted to the Emergency Center with a diagnosis of cancer confirmed by pathology (either hematologic malignancies or solid tumors).~2. Patients with either hematologic malignancies or solid tumors must either be currently undergoing active cancer treatment (received chemotherapy, radiotherapy, chemoradiotherapy, blood or bone morrow transplant, surgery, immunotherapy anytime during the past month) or not receiving any cancer treatments in past month.~3. Patient's chief complaint upon admission to the EC must be one or more of the following four conditions: a. fever (38.3°C or higher) in past 24 hours b. pain c.any chemotherapy-related GI toxicities (such as nausea, vomiting, diarrhea, or constipation) d.shortness of breath~4. Patients must be able to read and write English~5. Patients must agree to participate and must sign the Informed Consent~6. Patients must be 18 years or older (minimal numbers of children are evaluated in the EC)~7. Patients must be able to complete the survey tool independently (without input or influence from their caregivers).~8. Patients whose performance status allows them to complete the survey (i.e., patients who do not have altered mental/cognitive status, and patients without emergent illness and hemodynamic instability---for example, status epilepticus, sepsis, cardiac arrest, and any life-threatening condition).~Exclusion Criteria:~1) Patients who were already enrolled on this protocol in a previous visit to this EC will not be enrolled again, regardless of their reasons for the current EC visit (same or different reason).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fatigue in Emergency Center Patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of metastatic lung cancer, with histologic confirmation of the primary NSCLC histology and with at least one lesion amenable for intra-tumoral injection of MV-NIS.~* Patient meets the FDA-approved indication for Atezolizumab treatment in NSCLC.~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1.~* Ability to provide informed consent.~* Adequate hematological, liver and kidney function.~* Must be willing to implement contraception throughout study and for the 8 weeks following last study drug administration.~Key Exclusion Criteria:~* Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration~* Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation).~* Pregnant women.~* Nursing women.~* Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment.~* Allergy to measles vaccine or history of severe reaction to prior measles vaccination.~* History of organ transplantation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MV-NIS and Atezolizumab (Type: EXPERIMENTAL): MV-NIS will be administered intratumorally as a single dose on day 1. Atezolizumab will be given at day 15 and then every 3 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with active (HBI \>10) refractory inflammatory and/or perianal fistulizing Crohn's disease who are prescribed infliximab as standard of care by their gastroenterologist.~Exclusion Criteria:~* Pregnant women.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Remicade (Type: EXPERIMENTAL): Subjects will begin with receiving infliximab at 5 mg/kg for the first visits. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Oxygenation in Septic Patients Using Vasopressors - the Conscious Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* Septic shock patients in ICU department requiring vasopressor therapy~Exclusion Criteria:~* Damage to the frontal lobes corresponding to the area where SCO2 is monitored~* Patients in pharmacological studies~* Patients with known intracranial vascular anomalies or cerebral aneurysms~* Patients where vasoactive medication is started before cerebral oxymetry is established~* Patients with known neurological disease~* Patients with undergone cerebral insult, transient ischemic attack or carotid stenosis~* Patients who have been resuscitated after cardiac arrest in connection with this hospital stay~* Patients with a body temperature below 35 degrees Celsius when establishing monitoring

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Septic shock and vasopressor (Type: None): Measuring cerebral oxymetry (SCO2) first 24 hours in septic shock and given vasopressors.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Plerixafor in Diabetic Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 1 or type 2 diabetes~* Men of 18-85 years or post-menopausal women \<85 years of age~* Presence of neuroischemic or ischemic diabetic wound(s) of the leg(s) / foot(s) Texas grade 3 or 4, with or without infection.~* Ability to provide informed consent.~Exclusion Criteria:~* Sepsis~* Dialysis or severe chronic kidney disease (eGFR \<20ml/min/1.73 mq)~* Advanced liver disease (defined as cirrhosis or transaminases \>3 times ULN)~* Clinically relevant abnormalities in white blood cell counts at baseline.~* Hematologic disorders (lymphoma, myeloma, acute or chronic leukemia, chronic myeloproliferative disorders)~* Known or highly suspected solid cancer~* Women with childbearing potential~* Known hypersensitivity to Mozobil (Plerixafor or its components)~* Inability to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Plerixafor (Type: EXPERIMENTAL): Single subcutaneous injection of Plerixafor (0.24 mg/kg)
- Placebo (Type: PLACEBO_COMPARATOR): Single injection of an equal volume of NaCl solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Drug Eluting Balloon for Prevention of Constrictive Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* at least one target lesion with a stenosis severity ≥ 50% in one coronary segment with a diameter ≤ 2.5 mm~* age \> 18 years~* weight \> 45 kg~* patient suitable for balloon dilatation and not suitable for elective implantation of a drug eluting stent~* insulin-dependent or non-insulin-dependent diabetes mellitus~* length of lesion ≥ 15 mm~Exclusion Criteria:~* Life expectancy \< 12 months~* In-Stent restenosis~* planned coronary bypass or heart valve OP~* ST elevation myocardial infarction within the last 72 hours~* cardiogenic shock~* renal impairment or liver dysfunction (creatinine \> 2.0 mg/dl, AST/ALT \> 3x of normal value~* incompliance~* pregnant or breastfeeding women or women who like to be pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel coated balloon catheter (Type: ACTIVE_COMPARATOR): Paclitaxel coated balloon catheter IN.PACT Falcon
- uncoated balloon catheter (Type: ACTIVE_COMPARATOR): uncoated balloon catheter sprinter legend

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Latarjet-type Procedure Using the SEM Positioner: Using a Scan to Assess Consolidation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must have given his/her informed and signed consent~* The patient must be insured or beneficiary of a health insurance plan~* The patient was operated for chronic anterior shoulder instability (defined by a history of at least two true dislocations and an ISIS score\> 2) 6 weeks ago (+/- 5 days)~Exclusion Criteria:~* The patient is participating in another study~* The patient is in an exclusion period determined by a previous study~* The patient is under judicial protection, under tutorship or curatorship~* The patient refuses to sign the consent~* It is impossible to correctly inform the patient~* The patient is pregnant, parturient, or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Study population (Type: EXPERIMENTAL): The patients included have been operated for chronic anterior shoulder instability by a Latarjet-type bone block procedure using the SEM (Science Et Medecine) positioning tool within the past 3 months.~Intervention: Scan of shoulder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Asymptomatic Colonization With S. Aureus After Therapy With Linezolid or Clindamycin for Acute Skin Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* having an ABSSSI or a minor cutaneous abscess treated in the ED~* age 18 years or older~* any one or more of the following co-morbidities:~  * diagnosis of diabetes mellitus~ * obesity with a BMI \>35~ * chronic kidney disease~ * coronary artery disease~ * peripheral vascular disease~Exclusion Criteria:~* known history of or current thrombocytopenia~* Currently taking anti-depression medication~* Current or recent hospitalization~* Known current alcohol or drug abuse~* Known or suspected hypersensitivity to any ingredient of the study drugs~* Irregular heart rate and blood pressure measurements~* Fevers or low body temperature~* Known psychiatric condition~* Superficial skin infection~* Skin infection caused from an animal bite~* Recent treatment with antibacterials~* Pregnancy~Other protocol related inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- linezolid (Type: ACTIVE_COMPARATOR): None
- Clindamycin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety and Pharmacokinetics of Topically Applied 40% Lidocaine Gel Compared With Placebo in Subjects With Acute Herpes Zoster (Shingles) Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is a male or female ≥ 18 years of age and ≤ 85 years of age.~2. Subject has brush-evoked allodynic pain intensity score ≥ 4 using the NPRS as determined by pain assessment during the physical examination at screening.~   a. Onset must have occurred ≤ 20 days prior to randomization~3. Subject has an average daily pain intensity score of ≥ 4 using the NPRS as determined by pain assessment during the physical examination at screening.~4. Subject must have a diagnosis of herpes zoster (shingles).~5. Subject has rash limited to trunk and limbs, with a total surface area of up to 300 cm2.~Exclusion Criteria:~1. Subject has an active herpes zoster lesion on the face, head, neck, genital or rectal areas.~2. Subject has rash limited to trunk and limbs, with a total surface area greater than 300 cm2.~3. Subject has a known history of allergic reaction, hypersensitivity, or clinically significant intolerance to lidocaine, ingredients of the study drug, or local anesthetics of the amide type.~4. Subject has target skin area (allodynic area and surrounding skin) that is not intact, is inflamed, or in the opinion of the Principal Investigator, consistent with rash due to acute herpes zoster.~5. Subject has any other form of pain that was not discernible from herpes zoster (shingles) allodynia.~6. Subject is taking Class I antiarrhythmic drugs (e.g., tocainide, mexiletine), or medications that could interact with the study drug or interfere with its evaluation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- CNTX-2022 (lidocaine gel, 40%) (Type: EXPERIMENTAL): Application of 1mL CTNX-2022 (40% Anhydrous Lidocaine Gel) topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.
- Placebo (Type: PLACEBO_COMPARATOR): Application of 1mL placebo topically applied to 300cm squared outlined area once daily (in the morning) for 8 days at the study site.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent before any trial related activities.~* Male or female subjects of 40 - 65 years of age.~* Diagnosis of diabetes mellitus defined as HbA1c level of ≥ 6.5% (for newly diagnosed diabetes) or based on medical history.~* Presence of peripheral arterial disease with resting ankle-brachial index (ABI) of 0.41-0.90 inclusive~Exclusion Criteria:~* Females of childbearing potential: pregnancy, breast-feeding, and the intention of becoming pregnant.~* Recent stroke attack, myocardial infarction/unstable angina/acute coronary syndrome, coronary artery bypass surgery (CABG) or percutaneous transluminal coronary angioplasty (PTCA)/stent within 3 (three) months prior to screening.~* Impaired liver function: serum ALT \> 2.5 times upper limit of normal.~* Impaired renal function: serum creatinine ≥ 1.5 times upper limit of normal.~* Concomitant use of other antithrombosis drugs or any antiplatelets other than the study medication.~* Subjects with concurrent herbal (alternative) medicines or food supplements~* Subjects with any other disease state, including chronic or acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could interfere with trial participation or trial evaluation.~* Subjects with high risk of bleeding:~* Subjects with prior experience with DLBS1033 or other oral lumbrokinase products.~* Subjects with known or suspected allergy to any of study medications used in the study, including other lumbrokinase products.~* Subjects with known or suspected allergy or resistant to aspirin.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DLBS1033 (Type: EXPERIMENTAL): DLBS1033 tablet is administered at the dose of 490 mg, one tablet three times daily, every day for twelve weeks of study period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet is administered one tablet three times daily, every day for twelve weeks of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues